Galecto reports safety and efficacy of GB0139 in COVID-19; 21% mortality reduction in high-risk subgroup

Damora Therapeutics, Inc.

Study met primary safety endpoint: no treatment-related adverse events in 20 GB0139 patients.
Target engagement confirmed: statistically significant reduction in serum galectin-3 (p<0.01).
GB0139-treated patients had significantly greater rate of decline in oxygen requirement vs standard of care.
In high-risk subgroup, 21% mortality reduction observed; company plans co-development for COVID-19.
GALACTIC-1 IPF trial: amendment to reduce target patients, topline expected mid-2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.